TIGER KOSDAQ150 ETF (232080)
Market Closed
11 Aug, 06:30
KRX SM KRX SM Primary ₩
15,065. 00
+5
+0.0332%
₩
- Market Cap
0.49% Div Yield
3.54M Volume
₩ 15,060
Previous Close Want to track 232080 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
232080 closed today higher at ₩15,065, an increase of 0.0332% from yesterday's close, completing a monthly decrease of -11.3824% or -₩1,935. Over the past 12 months, 232080 stock lost -4.8326%.
232080 pays dividends to its shareholders, with the most recent payment made on May 06, 2026. The next estimated payment will be in 5 days ago on Aug 06, 2026 for a total of ₩40.
The stock of the company had never split.
The company's stock is traded on one exchange.
232080 Chart
TIGER KOSDAQ150 ETF (232080) FAQ
What is the stock price today?
The current price is ₩15,065.00.
On which exchange is it traded?
TIGER KOSDAQ150 ETF is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 232080.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.49%.
What is its market cap?
As of today, no market cap data is available.
Has TIGER KOSDAQ150 ETF ever had a stock split?
No, there has never been a stock split.
TIGER KOSDAQ150 ETF Profile
| KRX SM Exchange | FR Country |
Overview
Sartorius Stedim Biotech S.A. is a cornerstone in the biopharmaceutical industry, providing a vast array of instruments and consumables used globally. The company's extensive product portfolio caters to the needs of medication manufacturers, food industries, chemical sectors, as well as research and development laboratories. Founded in 1870, with its headquarters in Aubagne, France, it stands as a subsidiary of Sartorius AG. Its offerings facilitate numerous critical processes in the biopharmaceutical production and development chain, from cell cultivation to the transportation of biological products.
Products and Services
- Cell Lines & Cell Culture Media: These foundational components are essential for the cultivation and maintenance of cells in the laboratory, enabling the growth of precise and replicable biological products.
- Bioreactors: Sartorius Stedim Biotech S.A. provides cutting-edge bioreactors that are integral for the cell cultivation process, facilitating the development of vaccines, enzymes, and other biotherapeutic agents.
- Separation, Purification, and Concentration Products: A comprehensive range of products designed for the critical stages of biopharmaceutical manufacturing, ensuring the purity and potency of the final products.
- Storage and Transportation Systems: Solutions for the safe handling, storage, and transportation of intermediate and finished biological products, addressing the challenges of maintaining product integrity.
- Service Offerings: The company extends its expertise through services in cell cultivation, fermentation, separation, purification, and fluid management, further supporting the biopharmaceutical production cycle.
- Batch and Intensified Chromatography Systems: These systems are tailored for smaller molecules, like oligonucleotides, peptides, and insulin, optimizing purification processes for efficiency and effectiveness.
- Recombinant Albumin-Based Solutions: Offering a safe and animal-free alternative for cell culture growth mediums, enhancing the productivity and reliability of biopharmaceutical products.
- Data Analytics Software: Advanced software solutions for modeling and optimizing the processes of biopharmaceutical development and production, empowering companies with data-driven insights for process improvement.
Contact Information
Address: Zone Industrielle Les Paluds
Phone: 33 4 42 84 56 00
Website: https://www.sartorius.com
